|
(MoneyNewsWire.Net, September 30, 2016 ) "Glaucoma - US Drug Forecast and Market Analysis to 2023". The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect.
Description-
Summary
Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aeries Rhopressa, Bausch & Lombs Vesneo (latanoprost bunod), and Inoteks trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma marke
To Free Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=821919
GlobalData estimates that drug sales for glaucoma in the US during 2013 reached $1.7 billion, making this the largest market within the 7MM. After an initial period of minimal growth, GlobalData estimates that the glaucoma market will follow a steady growth trend from 2018 onwards. This growth is mainly attributed to the expected introduction of five pipeline products during the forecast period, and the overall increase in prevalent cases of glaucoma that is mostly due to an aging society in the US.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Scope
- Overview of Glaucoma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
To Enquire Regarding This Report @ http://www.researchmoz.us/enquiry.php?type=E&repid=821919
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 17
3.2 Classification 20
3.3 Symptoms 21
3.4 Diagnosis 22
4 Disease Management 27
4.1 Diagnosis and Treatment Overview 27
4.1.1 Diagnosis 27
4.1.2 Treatment Guidelines 28
4.1.3 Leading Prescribed Drugs 30
4.1.4 Clinical Practice 30
4.2 US 32
5 Competitive Assessment 37
5.1 Overview 37
5.2 Product Profiles - Main Brands and Drug Classes 39
5.2.1 Xalatan (latanoprost) 39
5.2.2 Lumigan (bimatoprost) 45
5.2.3 Travatan (travoprost) 49
5.2.4 Tapros (tafluprost) 53
5.2.5 Beta Blockers 60
5.2.6 Carbonic Anhydrase Inhibitors 65
5.2.7 Alpha-Adrenergic Agonists 69
5.2.8 Simbrinza (brinzolamide + brimonidine) 72
5.2.9 Glanatec (ripasudil hydrochloride hydrate) 75
6 Unmet Need and Opportunity 81
6.1 Overview 81
6.2 Simplified Dosing Regimen 85
6.2.1 Unmet Need 85
6.2.2 Gap Analysis 86
6.2.3 Opportunity 89
6.3 Reminder Systems 90
6.3.1 Unmet Need 90
6.3.2 Gap Analysis 90
6.3.3 Opportunity 91
6.4 Long-Acting Therapy 92
6.4.1 Unmet Need 92
6.4.2 Gap Analysis 93
6.4.3 Opportunity 94
6.5 New Classes of IOP-Lowering Drugs 96
6.5.1 Unmet Need 96
6.5.2 Gap Analysis 98
6.5.3 Opportunity 99
For More Information Kindly Contact:
ResearchMoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
United States <||>rnhttp://www.researchmoz.us,
Blog - http://bit.ly/2b1Ayn6
866-997-4948 (Us-Canada Toll Free),
+1-518-621-2074,
Email to: sales@researchmoz.us,
Researchmoz Global Pvt.Ltd
Researchmoz, Mr. Nachiket Ghumare
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
|
